注冊以創建關於儀器的通知
你所追隨的作者的經濟活動和內容
免費註冊 已有帳戶？ 登入
📈 2025年，認真想投資? 邁出第一步，先拿下InvestingPro 五折優惠
領取優惠
206.830
-1.400
-0.67%
10/01 - 關閉. EUR 貨幣
- 晨星評級:
- 總資產: 259.47M
Allianz Biotechnologie A EUR
206.830
-1.400
-0.67%
0P00000CML綜觀
你可在本頁找到深入的德盛全球生物科技基金EUR-INC公司檔案，包括0P00000CML的主要管理層、總資產、投資策略及聯絡資料，以及各類其他資訊。
投資策略
此基金於一九九八年一月成立。目標是透過投資從事研究、開發或生產生物科技、藥物或醫學科技的跨國公司，實現長期資本增值。
聯絡資訊
地址
L-2633 Senningerberg
Frankfurt am Main, 60323
Germany
Frankfurt am Main, 60323
Germany
電話
+49 (0) 69 2443-1140
傳真
Milano
主要管理層
| 名稱 | 主旨 | 成立於 | 直至 |
|---|---|---|---|
| Christopher Chin | - | 2018 | now |
| Peter Pirsch | Senior Portfolio Manager | 2019 | 2023 |
| 自傳 | Mr. Pirsch is a senior portfolio manager, a senior analyst and a director with Allianz Global Investors, which he joined in 2018. He has management and research responsibilities for the Health Care team. Mr. Pirsch has 20 years of investment-industry experience. He previously worked at Aptigon Capital, Visium Asset Management, Surveyor Capital, Fred Alger Management and C.R. Bard. Before that, Mr. Pirsch was an associate director at UBS Investment Bank and an analyst at Wells Fargo. He has a B.A. in economics and international relations from Bucknell University, and an M.B.A. with a certificate in health sector management from Duke University, Fuqua School of Business. Mr. Pirsch is a CFA charterholder. | ||
| Kimberlee W. Millar | Vice President | 2018 | 2021 |
| 自傳 | Ms. Millar is a portfolio manager, analyst and director with Allianz Global Investors, which she joined in 2005. As a generalist for the Disciplined Equities group, her primary responsibility is conducting company research; she also helps improve the group’s overall investment processes and contributes toward its portfolio-management efforts. Ms. Millar has 23 years of investment industry experience. She previously worked as an assistant economist at the Investment Company Institute in Washington, D.C., producing mutual-fund-industry research for investment-management firms’ research and marketing departments. Before that, Ms. Millar worked at Heiden Associates Inc., an economic consulting firm in Washington, D.C. She has a B.A. in economics from the University of Calgary, Canada, and an M.A. in economics from Queen’s University, Canada. Ms. Millar is a CFA charterholder and a member of the CFA Institute. | ||
| Hugo Ong | - | 2018 | 2021 |
| Peter Pirsch | Senior Portfolio Manager | 2018 | 2019 |
| 自傳 | Mr. Pirsch is a senior portfolio manager, a senior analyst and a director with Allianz Global Investors, which he joined in 2018. He has management and research responsibilities for the Health Care team. Mr. Pirsch has 20 years of investment-industry experience. He previously worked at Aptigon Capital, Visium Asset Management, Surveyor Capital, Fred Alger Management and C.R. Bard. Before that, Mr. Pirsch was an associate director at UBS Investment Bank and an analyst at Wells Fargo. He has a B.A. in economics and international relations from Bucknell University, and an M.B.A. with a certificate in health sector management from Duke University, Fuqua School of Business. Mr. Pirsch is a CFA charterholder. | ||
| John R. Schroer | Portfolio Manager | 2014 | 2018 |
| 自傳 | Mr. Schroer, CFA, is a portfolio manager and a director with Allianz Global Investors, which he joined in 2014. He is the sector head of the Health Care team. He was previously the president of Schroer Capital, L.P.; an equity analyst with HealthCor Management, L.P.; a managing member and portfolio manager for ITROS Capital Management, LLC; a global partner, senior vice president, and portfolio manager for INVESCO; and an analyst for Trust Company of the West. Mr. Schroer has a B.S. in history and international relations and an M.B.A. in finance from the University of Wisconsin. | ||
| Paul A. Wagner | Senior Research Analyst | 2012 | 2014 |
| 自傳 | Mr. Wagner, CFA, is a portfolio manager, a senior research analyst and a director with Allianz Global Investors, which he joined in 2006. He has biotechnology responsibilities for the US Health Care team and has 14 years of investment-industry experience. Mr. Wagner previously worked at PDL BioPharma in corporate and business development, and was a vice president and senior equity-research analyst in the biotechnology sector at Lehman Brothers. He has a B.S. in chemistry from the University of Wisconsin and a Ph.D. in chemistry from the California Institute of Technology. | ||
| Nicole Papassavvas | - | 2008 | 2012 |
| Javier Latorre | - | 2007 | 2012 |
在留言中加插圖表
確認封鎖
你確定要封鎖 %USER_NAME%？
此舉將會令你與 %USER_NAME% 之間無法看見對方的Investing.com貼文。
%USER_NAME% 已成功加入你的封鎖清單
你剛解除此人的封鎖，必須等候 48 小時後才可再次封鎖。
舉報此評論
我覺得這個評論是:
評論被加標記
謝謝！
您的報告已被發送到我們的版主審核